age; AML
Item
1. subjects of 18 years of age or major, with diagnosis of primary or secondary aml, confirmed cytologically, that fulfill one of the following conditions:
boolean
C0001779 (UMLS CUI [1])
C0023467 (UMLS CUI [2])
complete remission; conventional treatment
Item
do not reach a cr after the conventional treatment.
boolean
C0677874 (UMLS CUI [1])
C2945704 (UMLS CUI [2])
relapse
Item
relapse in the first 12 months after a cr. during remission, patients can have be treated by a transplant. the relapse is defined as the presence of blasts in peripheric blood or the presence of >5 % of blasts in mo.
boolean
C0035020 (UMLS CUI [1])
Study Subject Participation Status
Item
not participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])
ecog
Item
2. ecog < o = 2
boolean
C1520224 (UMLS CUI [1])
Chemotherapy Intensive
Item
3. considered suitable patients for an intensive chemotherapy
boolean
C3665472 (UMLS CUI [1,1])
C2827726 (UMLS CUI [1,2])
informed consent
Item
4. informed consent
boolean
C0021430 (UMLS CUI [1])
radiotherapy Pelvis; radiotherapy spinal
Item
1. pelvic or spinal radiotherapy in 4 weeks before the incorporation in the protocol.
boolean
C1522449 (UMLS CUI [1,1])
C0030797 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0521329 (UMLS CUI [2,2])
acute promyelocytic leukaemia
Item
2. acute promyelocytic leukaemia
boolean
C0023487 (UMLS CUI [1])
chemotherapy fludarabine; chemotherapy Topotecan
Item
3. first line chemotherapy for aml which has contained fludarabine or topotecan.
boolean
C3665472 (UMLS CUI [1,1])
C0059985 (UMLS CUI [1,2])
C3665472 (UMLS CUI [2,1])
C0146224 (UMLS CUI [2,2])
Hepatitis, Chronic; Liver Cirrhosis
Item
4. active or chronic hepatitis or hepatic cirrhosis.
boolean
C0019189 (UMLS CUI [1])
C0023890 (UMLS CUI [2])
HIV positve
Item
5. positivity known to the virus of the human immunodeficiency (hiv)
boolean
C0019682 (UMLS CUI [1,1])
C1446409 (UMLS CUI [1,2])
pregnant; Lactating
Item
6. pregnant or breastfeeding patients.
boolean
C2828358 (UMLS CUI [1,1])
C0549206 (UMLS CUI [1,2])
Hepatic Insufficiency; Renal Insufficiency
Item
7. patients with deterioration of the functions hepatic or renal, defined for the following values base them of laboratory:
boolean
C1306571 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
Aspartate aminotransferase measurement; Alanine aminotransferase measurement
Item
ast or alt >2,5 times the top limit of the normality of the center (lsnc)
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
alkaline phosphatase measurement
Item
alkaline phosphatase >2,5 times the lsnc
boolean
C0201850 (UMLS CUI [1])
Bilirubin, total measurement
Item
total bilirubin value >2 times the lsnc
boolean
C0201913 (UMLS CUI [1])
Creatinine measurement
Item
creatinine value >2 times the lsnc after a suitable hydration
boolean
C0201975 (UMLS CUI [1])
major surgery
Item
8. precedents of intervention of major surgery in 2 weeks before the incorporation in the protocol.
boolean
C0679637 (UMLS CUI [1])
comorbidity
Item
9. patients with disease serious or not controlled (for example not controlled diabetes, infection, hypertension, etc.).
boolean
C0009488 (UMLS CUI [1])
cytotoxic drugs; hydroxyurea Except for
Item
10. patients who have received other cytotoxic drugs (except hydroxyurea to reduce the leucocytosis) as treatment of the current relapse or of the resistance, in 4 weeks before the protocol.
boolean
C0304497 (UMLS CUI [1])
C0020402 (UMLS CUI [2,1])
C0332300 (UMLS CUI [2,2])
hypersensitivity
Item
11. patients with hypersensitivity known to someone of the drugs of the protocol.
boolean
C0020517 (UMLS CUI [1])
growth factors therapy; sensibilization
Item
12. patients treated previously with growth factors with purposes of sensibilization.
boolean
C0018284 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0020971 (UMLS CUI [2])
Compliance behavior Limited Comorbidity
Item
13. patients with psychological, intellectual or sensitive dysfunction that can reduce his capacity of comprehension and fulfillment of the protocol.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Fludarabine, Cytarabine and Topotecan therapy
Item
14. patients treated before with flat.
boolean
C0796415 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])